bardoxolone

Graphic showing arrows missing the bullseye on a target

Biotech

Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga

Reata and Kyowa Kirin gave bardoxolone the old college try, but ultimately decided to end development after a new late-stage failure.

Max Bayer May 10, 2023 10:22am

red light stoplight

FDA advisers unanimously reject Reata's kidney disease drug

Dec 8, 2021 5:00pm